

PRODUCT INFORMATION




Cefoselis (sulfate)

Item No. 34414

CAS Registry No.: 122841-12-7
Formal Name: (6R,7R)-7-[[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosulfate

Synonym: FK-037
MF: C₁₉H₂₂N₈O₆S₂ • H₂SO₄
FW: 620.6
Purity: ≥98%
UV/Vis.: λ_{max}: 261 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cefoselis (sulfate) is supplied as a solid. Aqueous solutions of cefoselis (sulfate) can be prepared by directly dissolving the solid in aqueous buffers. The solubility of cefoselis (sulfate) in PBS (pH 7.2) is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Cefoselis is a cephalosporin antibiotic.¹ It is active against clinical isolates of extended-spectrum β-lactamase-producing *E. coli*, *K. pneumoniae*, and *P. mirabilis*, as well as *C. freundii*, *E. aerogenes*, *E. cloacae*, *S. marcescens*, and *P. vulgaris* with susceptibility rates ranging from 56.7 to greater than 94%. Cefoselis is protective against lethality in mouse models of systemic methicillin-susceptible *S. aureus* (MSSA), low-level methicillin-resistant *S. aureus* (L-MRSA), high-level methicillin-resistant *S. aureus* (H-MRSA), *S. pneumoniae*, *E. coli*, *K. pneumoniae*, or *P. aeruginosa* infection (ED₅₀S = ≤0.025-1.56 mg/kg).¹ It reduces the number of renal colony forming units (CFUs) in a mouse model of *S. epidermidis*-induced ascending pyelonephritis when administered at a dose of 50 mg/kg.

References

1. Cheng, J.-W., Su, J.-R., Xiao, M., et al. *In vitro* activity of a new fourth-generation cephalosporin, cefoselis, against clinically important bacterial pathogens in China. *Front. Microbiol.* **11**, 180 (2020).
2. Mine, Y., Watanabe, Y., Sakamoto, H., et al. *In vivo* antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin. *J Antibiot. (Tokyo)* **46(1)**, 88-98 (1993).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM